Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The conversation discusses a community called PHG, which focuses on experimental hair loss treatments and scientific approaches to hair regrowth. It mentions treatments like Minoxidil, finasteride, and RU58841, and highlights interest in new treatments like Setipripant, Histogen, and Replicel.

The user plans to aggressively treat hair loss by using 1.25mg finasteride daily, 1mL minoxidil twice daily, and topical dutasteride with microneedling weekly, despite experiencing side effects from finasteride previously. They intend to switch to a maintenance routine with topical minoxidil and dutasteride after regaining hair.

The user reported positive hair regrowth results after six months of using 0.5 mg finasteride and nanoxidil, despite experiencing initial side effects like testicular pain and changes in libido. They noted that nanoxidil was chosen over minoxidil due to less scalp irritation.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

People are discussing various hair loss treatments, including finasteride, minoxidil, RU58841, and new potential treatments like vdphl01, ABS-201, and KX-826. Some express hope in future developments like hair cloning and CRISPR, while others emphasize acceptance and sticking with current treatments.

A 49-year-old user shared their 10-month hair recovery journey using finasteride, topical minoxidil, and considering oral minoxidil, with plans to evaluate dutasteride at 18 months. They reported noticeable hair thickening and reduced self-consciousness, despite a slow process and initial setbacks.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The user reports progress in treating hair loss using oral minoxidil, finasteride, topical RU58841, a derma stamp, and ketoconazole shampoo. They experience no side effects from RU58841 and believe it acts locally.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A 49-year-old is updating on hair regrowth progress using finasteride, minoxidil foam, tretinoin cream, and ketoconazole shampoo. They report thicker, darker hair and reduced scalp itch after switching to minoxidil foam.

The user shared progress on hair regrowth after a third verteporfin procedure, using oral dutasteride, extended-release oral minoxidil, and occasional microneedling. The results were positively received by others.

The conversation discusses concerns about getting a hair transplant with the potential release of a new treatment, PP405, which may regrow dormant hair follicles. The user is currently using Minoxidil, Derma, and Keto but is waiting to start finasteride or dutasteride.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.